Cardio Ed

#FAME3 trial was recently published in #NEJM. Patients with three-vessel coronary artery disease have been found to have better outcomes with coronary-artery bypass grafting (#CABG) than with percutaneous coronary intervention (#PCI), but studies in which PCI is guided by measurement of fractional flow reserve (#FFR) have been lacking. The current trial tried to fill in the knowledge gap.

#DeviceRelatedThrombosis after #LeftAtrialAppendageOcclusion is a problem which negates the very advantages of left atrial appendage occlusion. It increases the ischemic risk. The #LAAODRTregistry was a case control study of device related thrombosis in patients who received any of the left atrial appendage occlusion device like Watchman or ACP/Amulet, published in JACC. Both #Watchman and #ACP or #Amulet device are associated with this complication of device related Thrombosis.

This article was published in #JACC in July 2021, it discusses the predictors of device related thrombosis in patients with left atrial appendage occlusion device. It also evaluates the effect of device related thrombosis on mortality, ischemic risk and higher MACE.

Let's take a dive into this article published in JACC and find out what the authors of LAAODRT registry concluded.

#LAAODRTregistry

#Watchman

#ACP

#Amulet

#DeviceRelatedThrombosis

Follow Cardio-Ed for more content.

https://m.youtube.com/channel/UCVxInTblTpoy-THMuSxNyvw/videos

Cardio-Ed is now available on Apple Poscast, Google Podcast, Spotify and other major podcast platforms too. Now you can stay updated on the go. Listen to episodes.(New episodes should be immediately avaliable on Spotify; would feature on other platforms in a while).

Here are the links.

Apple

https://podcasts.apple.com/us/podcast/cardio-ed/id1570745864

Google Podcast

https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy81ZDRiOTgwMC9wb2RjYXN0L3Jzcw

Spotify:

https://open.spotify.com/show/3SLQ2g4Ii8hdFiy7i8LMRp?si=hWgPgwliQ5a5RY_nz-Q22g&utm_source=copy-link

Amazon Music

https://music.amazon.in/podcasts/4215cfdf-5121-438e-b355-14eaabed41e5/CARDIOED?ref=dm_sh_vn5xvDArGZGRCTh8YpK3Mdtff

Stitcher:

https://www.stitcher.com/podcast/cardioed

Podcastaddict:

https://podcastaddict.com/podcast/3368070

Breaker:

https://www.breaker.audio/cardio-ed

PocketCasts

https://pca.st/bprb5899

RadioPublic

https://radiopublic.com/cardioed-Woje3A

Podcast Index

https://podcastindex.org/podcast/3933141

Player FM

https://player.fm/series/cardio-ed

Listen Notes

https://www.listennotes.com/podcasts/cardio-ed-cardio-ed-Jk3r1sq5_VF/

(Also available on Deezer)

#Abelacimab for #VenousThromboembolism prevention after #TotalKneeReplacement, published in July 2021 edition of #NEJM.

#Abelacimab is #MonoclonalAntibody against #Factor XI, a key component of #intrinsicCoagulationPathway. It has been used in prevention of Venous Thromboembolism after Total Knee Replacement and compared to #Enoxaparin.

In this study published in #NEJM or the #NewEnglandJournalOfMedicine Abelacimab has been used in 4 doses and its safety and efficacy has been studied. Abelacimab blocks the intrinsic clotting pathways and may be a useful drug in our armamentarium of venous thromboembolism prevention after orthopaedic surgeries like total knee replacement.

To know about Abelacimab, intrinsic coagulation pathway inhibition and venous thromboembolism prevention after Total knee replacement watch this video.

Follow #Cardio-Ed for more such content on recent advances, recent guidelines and recent articles in the field of cardiology.

https://youtube.com/channel/UCVxInTblTpoy-THMuSxNyvw

#ADAPTABLE trial was recently published in NEJM 2021 and it was also presented at ACC 2021 conference. It compared #HighDoseAspirin and #LowDoseAspirin in patients receiving it for secondary prevention.

Follow Cardio-Ed for more such content. We discuss Recent advances, recent guidelines and recent articles in cardiology as well as core concepts in Cardiology.

https://youtube.com/channel/UCVxInTblTpoy-THMuSxNyvw

REHAB - HF trial was recently published in New England journal of medicine (NEJM) 2021 (July). It was also presented at the

American College of Cardiology Virtual Annual Scientific Session (ACC 2021).

The REHAB -HF trial tested the strategy of tailored rehabilitation program in older patients with acute heart failure.

Acute heart failure in older patients has its own problems.

In this podcast I discuss about the type of the patients enrolled in the REHAB - HF trial and its findings.

This important trial published in NEJM, july 2021 and presented at ACC 2021 is a landmark trial as far as the rehabilitation of heart failure patients is concerned.

To know more about the results of REHAB-HF trial published in NEJM 2021 and ACC 2021 listen to this podcast.

Role of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF) was published in GALACTIC- HF trial (NEJM 2021). Recently, in JACC the effect of ejection fraction on response to Omecamtiv mecarbil in patients enrolled in GALACTIC-HF trial was published.

In this presentation I have discussed both these studies together.

Omecamtiv mecarbil may find its place in newer guidelines for HFrEF.

To know more about Omecamtiv mecarbil in patients with HFrEF and both the trials published in NEJM and JACC listen to this podcast.

In stent restenosis is common after POBA. in the era of DES also, it is responsible for 10% of all PCI. In this podcast i have discussed about definition of ISR (in stent restenosis), classification of ISR (in stent restenosis), risk factors of ISR (in stent restenosis), investigations of ISR (in stent restenosis), management of ISR (in stent restenosis). What is the role of DAPT, drug coated balloon and drug eluting stent in management of ISR. What are the recommendations of EAPCI for ISR management.

When to use DEB? When to use DES?

Past, present and future of therapeutic hypothermia.

Targeted temperature management (TTM) or Therapeutic hypothermia is recommended for patients after cardiac arrest, but the supporting evidence is of low certainty.

TTM-2 trial was recently published in NEJM (June 2021).

The TTM-2 trial tried to answer the question if Therapeutic hypothermia is any better than normal temperature in patients who are in coma after being resuscitated from cardiac arrest.

I have briefly discussed the trial, also touching briefly the recent and upcoming trials of hypothermia protocol.

Do watch/ listen.

Heart Failure with Preserved Ejection Fraction (HFpEF) is responsible of more than half of the cases of heart failure. It is a difficult to diagnose and difficult to treat condition. In this lecture i have summarized the available and upcoming drugs and other treatment modalities and evidence supporting each decision we make in HFpEF management.

What should be the blood pressure of these patients? How to manage co-morbidities in HFpEF? What drugs to give? What treatments have no basis and should not be given? What drugs to watch out for in future? Is there anything else besides drugs and lifestyle management , which we can offer to the patients and is there any scientific basis of such treatment.

FLOWER- MI trial was published in NEJM May 2021.

The trial tested the strategy of FFR guided complete revascularization in STEMI and compared it to the angiography guided complete revascularization. I have discussed the trial in the podcast.